Tuesday was earnings day for several regional life science firms.

Salix Pharmaceuticals reported an 81 percent surge in revenues to $35.1 million in the second quarter compared to the same period in 2004. As a result, Salix (Nasdaq: SLXP) reported earnings of 13 cents per share. Sales of its lead intestinal drug Colazal surged 42 percent to $26.8 million.

“It is important to note that during the second quarter the company was able to achieve an 81 percent increase in total product revenue while total operating expenses increased only 19 percent,” said Adam Derbyshire, chief financial officer for Salix.

For details, see: www.salix.com/newsroom/20050809.asp

At Inspire Pharmaceuticals, its quarterly revenues tripled over 2004 to reach $9.6 million. Inspire is producing revenue in large part through the co-promotion and sale of the ophthalmic solution Elestat. Those sales produced $7.9 million, up more than 200 percent from 2004. By hitting sales targets set with partner Allergan, Inspire was able to recognize $1.6 million in previously deferred sales revenue.

Inspire also worked with Allergan to produce $1.7 million in sales of its ophthalmic drug Restasis. That’s an increase of more than 370 percent, the company said.

Expenses also increased at Inspire, climbing to $15.3 million from $12.8 million, due to its own drug development efforts.

Inspire (Nasdaq: ISPH) reported a loss of $4.7 million, or 11 cents a share, which is less than half the $9.7 million loss reported in 2004.

For details, see: ir.inspirepharm.com/phoenix.zhtml?c=120779&p=irol-newsArticle&ID=741068&highlight=

Icagen, meanwhile, reported a net loss of $4.9 million. Revenues totaled $1.7 million.

“Icagen continued to make excellent progress during the second quarter of 2005,” said Kay Wagoner, Icagen’s chief executive officer. “During the quarter, we activated a number of new clinical sites in our pivotal Phase III trial of ICA-17043 for the chronic oral treatment of sickle cell disease and also took steps to prepare for additional clinical trials for pediatric patients and sickle cell disease patients with concomitant pulmonary hypertension. Also during the quarter, the Company made progress in advancing a number of promising leads across our portfolio of research programs, including our advanced preclinical program for epilepsy and neuropathic pain.”

For details, see: www.icagen.com/